ArticleFrontiers in immunology2021
Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Autoimmune disease risk gene ANKRD55 promotes TH17 effector function through metabolic modulation.The Journal of experimental medicine · 2025Article
- Genome-Wide Aggregated Trans-Effects Analysis Implicates Deficient Type III Interferon Signaling as a Key Cause of Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- Glatiramer Acetate Modifies the Immune Profiles of Monocyte-Derived Dendritic Cells In Vitro Without Affecting Their Generation.International journal of molecular sciences · 2025Article
- Efficient count-based models improve power and robustness for large-scale single-cell eQTL mapping.medRxiv : the preprint server for health sciences · 2025Article
- Review of the potential value of serum interleukin levels as prognostic biomarkers of liver failure.World journal of clinical cases · 2024Review
- Causal effects of rheumatoid arthritis or ankylosing spondylitis on membranous nephropathy: a two-sample Mendelian randomization study.Clinical kidney journal · 2023Article
- Impact of Multiple Sclerosis Risk Polymorphism rs7665090 on MANBA Activity, Lysosomal Endocytosis, and Lymphocyte Activation.International journal of molecular sciences · 2022Article
- 3DFAACTS-SNP: using regulatory T cell-specific epigenomics data to uncover candidate mechanisms of type 1 diabetes (T1D) risk.Epigenetics & chromatin · 2022Article
- Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 9 institutions in 2 countries.
Jorge MenaInflammation & Biomarkers Group, Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain.
Iraide AllozaInflammation & Biomarkers Group, Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain.
Raquel Tulloch NavarroInflammation & Biomarkers Group, Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain.
Ane AldekoaInflammation & Biomarkers Group, Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain.
Javier Díez GarcíaMicroscopy Facility, Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain.
Ane Villanueva EtxebarriaKronikgune Institute for Health Services Research, Barakaldo, Spain.
Cecilia LindskogDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
Alfredo AntigüedadDepartment of Neurology, Cruces University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain.
Sabas BoyeroDepartment of Neurology, Cruces University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain.
María Del Mar Mendibe-BilbaoDepartment of Neurology, Cruces University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain.
Amaya Álvarez de ArcayaDepartment of Neurology, Txagorritxu University Hospital, Osakidetza-Basque Health Service, Bioaraba Health Research Institute, Vitoria-Gasteiz, Spain.
José Luis Sánchez MenoyoDepartment of Neurology, Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Galdakao, Spain.
Luciana MidagliaServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Noelia VillarrubiaDepartment of Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Sunny MalhotraServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Xavier MontalbanServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Luisa María VillarDepartment of Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Manuel ComabellaServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Koen VandenbroeckInflammation & Biomarkers Group, Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain.
BioCruces Health research Institute · ESUniversitat Autònoma de Barcelona · ESHospital de Cruces · ESHospital Universitario Ramón y Cajal · ESOsakidetza · ESOsasun Sistemen Ikerketa Institutua · ESSpanish Multiple Sclerosis Network · ESUniversity of the Basque Country · ESUppsala University · SE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intronic single-nucleotide polymorphisms (SNPs) in the
Indexed as
Genetic VariationAllelesAutoimmunityBenzoatesBiomarkersCarrier ProteinsCell DifferentiationCytokine Receptor gp130Dendritic CellsGene Expression RegulationGenetic Predisposition to DiseaseHumansImmunophenotypingLeukocytes, MononuclearMultiple SclerosisTetrahydronaphthalenesAm 580ANKRD55 protein, humanBenzoatesBiomarkersCarrier ProteinsCytokine Receptor gp130IL6ST protein, humanTetrahydronaphthalenesANKRD55autoimmuneIL6STmultiple sclerosissgp130
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.